QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Payam Nahid, Sundari Mase, Giovanni Battista Migliori et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 453 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

Alexander S. Pym, Andreas H. Diacon, Shenjie Tang et al. · European Respiratory Journal · 2015 · 341 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 200 citations

Medicine, Microbiology, Pharmacology +13

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Florian von Groote-Bidlingmaier, R. F. Patientia, Epifanio Sánchez et al. · The Lancet Respiratory Medicine · 2019 · 163 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Gabriella Ferlazzo, Erika Mohr-Holland, Chinmay Laxmeshwar et al. · The Lancet Infectious Diseases · 2018 · 136 citations

Pharmacy, Pharmacology, Pharmacotherapy +14